DIA Biosimilars 2013

Trevena

Trevena granted composition of matter patent for TRV027

Thursday, July 18, 2013 11:05 AM

Trevena, a clinical stage pharmaceutical company in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, said the U.S. Patent and Trademark Office has granted Trevena a composition of matter patent covering its development product TRV027.

More... »

Cenduit: Now with Patient Reminders

Trevena, Forest Labs to develop TRV027 for acute heart failure

Thursday, May 9, 2013 11:16 AM

Trevena, a clinical stage pharmaceutical company focused on G-protein coupled receptor (GPCR) biased ligands, and Forest Laboratories, a global pharmaceutical company, have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed phase IIa clinical trials. Trevena expects to commence a 500-patient multi-center phase IIb clinical trial in acute decompensated heart failure (ADHF) by year end.

More... »

CRF Health – eCOA Forum
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs